Anti Ia Antibodies In The Treatment Of Autoimmune Disease

First Published in 1988, this book offers a full, comprehensive guide to autoimmunity. Carefully compiled and filled with a vast repertoire of notes, diagrams, and references this book serves as a useful reference for students of medicine, and other practitioners in their respective fields.

This work focuses on the autoimmune processes that have now been proven to underlie a number of serious diseases, including diabetes mellitus, rheumatoid arthritis and multiple sclerosis. Papers explore the rapidly expanding developments in research on immune response and regulation, and their potential in the development of treatments for autoimmune diseases. The wide range of subjects covered here include: the nature of intracellular and cell surface-derived ``self'' antigens; competing theories of the generation of immune tolerance and their implications of current theories for research and treatment; possible links between autoimmunity and genetic complement deficiency; the contributions of interferons and class II HLA antigen expression to autoimmunity; and the potential of monoclonal antibodies and other biotechnological advances in treating human autoimmune conditions.

The Janeway's Immunobiology CD-ROM, Immunobiology Interactive, is included with each book, and can be purchased separately. It contains animations and videos with voiceover narration, as well as the figures from the text for presentation purposes.

This volume, written by well-known experts in the field, covers all aspects of Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV). The expression refers to a group of diseases, characterized by destruction and inflammation of small vessels. The clinical signs vary and affect several organs, such as the kidney, lung, skin, nervous system and others. The opening chapters give some historical hints, explain the genetic basis of the disease and provide insights into the pathogenesis derived from recent experimental studies and guides the reader through classification and nomenclature. A large part of the book is then devoted to a detailed description of the specific related diseases and their clinical presentations, the disease course, and potential complications. The advice regarding treatment is based on the best currently available evidence in this constantly evolving area. The book is part of Springer’s series Rare Diseases of the Immune System, which presents recently acquired knowledge on pathogenesis, diagnosis, and therapy with the aim of promoting a more holistic approach to these conditions. AAVs are systemic autoimmune diseases of unknown cause that affect small (to medium) sized blood vessels. They include granulomatosis with polyangiitis (formerly Wegener's granulomatosis), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (formerly Churg–Strauss syndrome). This volume will be an invaluable source of up-to-date information for all practitioners involved in the care of patients with these diseases.

Recent national, European and international diabetes meetings have seen controversial discussions on the potential benefit and also on ethical aspects of immune intervention in patients with Type 1 diabetes or in persons with a high risk of developing the disease.

With the contribution from more than one hundred CNS neurotrauma experts, this book provides a comprehensive and up-to-date account on the latest developments in the area of neurotrauma including biomarker studies, experimental models, diagnostic methods, and neurotherapeutic intervention strategies in brain injury research. It discusses neurotrauma mechanisms, biomarker discovery, and neurocognitive and neurobehavioral deficits. Also included are medical interventions and recent neurotherapeutics used in the area of brain injury that have been translated to the area of rehabilitation research. In addition, a section is devoted to models of milder CNS injury, including sports injuries.

Effective immunotherapies The next generation of immunotherapeutic agents